Document -
Exelixis selects Sobi as COMETRIQ european distributor for medullary thyroid cancer
Exelixis, Inc. and Sobi today announced that they have entered into a three-year agreement to support the distribution and commercialization of COMETRIQ (cabozantinib) for metastatic medullary thyroid cancer (MTC) in the European Union (EU) and potentially other countries.
-
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: .pdf
